Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, after the company halted two high-dose arms in its Phase 2 TROPOS trial of ...

Keros will cut 45% of its workforce, leaving 85 employees and saving about $17 million annually. No improvement in PVR or 6MWD was seen; higher pericardial effusions in cibotercept arms vs. placebo.

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in ...

LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company" ...

Takeda Pharmaceutical is expanding its prospects in hematology with a deal for rights to a drug advancing to pivotal testing in a type of blood cancer, giving the Japanese pharmaceutical giant an ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Keros Therapeutics shares plummeted Thursday after the ...

On Thursday, Keros Therapeutics, Inc. (NASDAQ:KROS) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in ...

Positive news for Merck regarding a pulmonary hypertension drug helped Keros. Keros has enough cash, it says, to last through Q3 2024. Keros has three therapies in its pipeline to treat blood and ...